Related references
Note: Only part of the references are listed.Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial
Jonas Oldgren et al.
EUROPEAN HEART JOURNAL (2019)
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
Renato D. Lopes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk
Philip Urban et al.
EUROPEAN HEART JOURNAL (2019)
Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention?
Felice Gragnano et al.
EUROPEAN HEART JOURNAL (2019)
An open-Label, 2 x 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial
Renato D. Lopes et al.
AMERICAN HEART JOURNAL (2018)
Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention Insights From the PIONEER AF-PCI Trial
Mathieu Kerneis et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2018)
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials
Francesco Costa et al.
LANCET (2017)
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)
Marco Roffi et al.
EUROPEAN HEART JOURNAL (2016)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof et al.
EUROPEAN HEART JOURNAL (2016)
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention The ROCKET AF Trial
Matthew W. Sherwood et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2016)
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
C. Michael Gibson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial
Willem J. M. Dewilde et al.
LANCET (2013)
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data
Rikke Sorensen et al.
LANCET (2009)
Share Paper
